High Glucose Triggers Nucleotide Imbalance through O-GlcNAcylation of Key Enzymes and Induces KRAS Mutation in Pancreatic Cells

Cell Metab. 2019 Jun 4;29(6):1334-1349.e10. doi: 10.1016/j.cmet.2019.02.005. Epub 2019 Mar 7.

Abstract

KRAS mutations are the earliest events found in approximately 90% of pancreatic ductal adenocarcinomas (PDACs). However, little is known as to why KRAS mutations preferentially occur in PDACs and what processes/factors generate these mutations. While abnormal carbohydrate metabolism is associated with a high risk of pancreatic cancer, it remains elusive whether a direct relationship between KRAS mutations and sugar metabolism exists. Here, we show that under high-glucose conditions, cellular O-GlcNAcylation is significantly elevated in pancreatic cells that exhibit lower phosphofructokinase (PFK) activity than other cell types. This post-translational modification specifically compromises the ribonucleotide reductase (RNR) activity, leading to deficiency in dNTP pools, genomic DNA alterations with KRAS mutations, and cellular transformation. These results establish a mechanistic link between a perturbed sugar metabolism and genomic instability that induces de novo oncogenic KRAS mutations preferentially in pancreatic cells.

Keywords: KRAS mutation; O-GlcNAcylation; PFK; RNR; RRM1; high glucose; nucleotide imbalance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylation / drug effects
  • Acetylglucosamine / metabolism*
  • Acetyltransferases / metabolism
  • Adult
  • Aged
  • Animals
  • Carcinoma, Pancreatic Ductal / chemically induced
  • Carcinoma, Pancreatic Ductal / genetics
  • Carcinoma, Pancreatic Ductal / metabolism
  • Carcinoma, Pancreatic Ductal / pathology
  • Cell Transformation, Neoplastic / chemically induced*
  • Cell Transformation, Neoplastic / genetics
  • Cell Transformation, Neoplastic / metabolism
  • Cells, Cultured
  • DNA Damage / genetics
  • Dose-Response Relationship, Drug
  • Enzymes / genetics
  • Enzymes / metabolism*
  • Female
  • Glucose / adverse effects
  • Glucose / pharmacology*
  • HEK293 Cells
  • Humans
  • Infant, Newborn
  • Male
  • Metabolic Networks and Pathways / drug effects
  • Metabolic Networks and Pathways / genetics
  • Mice
  • Mice, Inbred C57BL
  • Middle Aged
  • Mutagenesis / drug effects
  • Mutation / drug effects
  • Nucleotides / metabolism*
  • Pancreas / drug effects*
  • Pancreas / metabolism
  • Pancreatic Neoplasms / chemically induced
  • Pancreatic Neoplasms / genetics
  • Pancreatic Neoplasms / metabolism
  • Pancreatic Neoplasms / pathology
  • Protein Processing, Post-Translational / drug effects
  • Proto-Oncogene Proteins p21(ras) / genetics*
  • Proto-Oncogene Proteins p21(ras) / metabolism
  • Young Adult

Substances

  • Enzymes
  • KRAS protein, human
  • Nucleotides
  • Acetyltransferases
  • Proto-Oncogene Proteins p21(ras)
  • Glucose
  • Acetylglucosamine